Exercise and the Prevention of Oesophageal Cancer (EPOC) study protocol: A randomized controlled trial of exercise versus stretching in males with Barrett's oesophagus

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Winzer, Brooke M ^a   Paratz, Jennifer D ^a   Reeves, Marina M ^a   Whiteman, David C ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; TUMOR MARKER;

ADULT; AEROBIC EXERCISE; AGED; ARTICLE; AUSTRALIA; BARRETT ESOPHAGUS; BODY COMPOSITION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; EXERCISE; FITNESS; GASTROESOPHAGEAL REFLUX; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; OBESITY; RANDOMIZED CONTROLLED TRIAL; RESISTANCE TRAINING; RISK FACTOR; STRETCHING; ADENOCARCINOMA; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; ESOPHAGUS TUMOR; KINESIOTHERAPY; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRECANCER; PRIMARY PREVENTION; RISK ASSESSMENT; SEDENTARY LIFESTYLE; STRETCHING EXERCISE; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; EXERCISE THERAPY; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MUSCLE STRETCHING EXERCISES; OBESITY; OVERWEIGHT; PRECANCEROUS CONDITIONS; PRIMARY PREVENTION; QUEENSLAND; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SEDENTARY LIFESTYLE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954614157     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-292     Document Type: Article

References (71)

1. Blot WJ, Devesa SS, Kneller RW. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287-1296. 10.1001/jama.265.10.1287, 1995976.
2. Lord RV, Law MG, Ward RL, Giles GG, Thomas RJ, Thursfield V. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998, 13(4):356-362. 10.1111/j.1440-1746.1998.tb00646.x, 9641297.
3. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part I: Overall and upper gastrointestinal diseases. Gastroenterology 2009, 136:376-386. 10.1053/j.gastro.2008.12.015, 19124023.
4. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002, 99:860-868. 10.1002/ijc.10427, 12115489.
5. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97(2):142-146. 10.1093/jnci/dji024, 15657344.
6. Kendall BJ, Whiteman DC. Temporal changes in the endoscopic frequency of new cases of Barrett's oesophagus in an Australian health region. Am J Gastroenterol 2006, 101:1178-1182. 10.1111/j.1572-0241.2006.00548.x, 16771933.
7. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
8. Polednak AP. Trends in survival for both histological types of esophageal cancer in US Surveillance, Epidemiology and End Results areas. Int J Cancer 2003, 105:98-100. 10.1002/ijc.11029, 12672037.
9. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340:825-831. 10.1056/NEJM199903183401101, 10080844.
10. World Cancer Research Fund/American Institute for Cancer Research The second expert report: food, nutrition, physical activity and the prevention of cancer: a global perspective. 2007, Washington DC: American Institute for Cancer Research, World Cancer Research Fund/American Institute for Cancer Research.
11. Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006, 130(3):639-649. 10.1053/j.gastro.2005.12.016, 16530504.
12. Smith KJ, O'Brien SM, Smithers M, Gotley DC, Webb PM, Green A, Whiteman DC. Interactions among smoking, obesity and symptoms of acid reflux in Barrett's oesophagus. Cancer Epidemiol Biomarkers Prev 2005, 14:2481-2486. 10.1158/1055-9965.EPI-05-0370, 1481636, 16284367.
13. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005, 143:199-211.
14. Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, Webb PM, Green AC. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008, 57:173-180. 10.1136/gut.2007.131375, 17932103.
15. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007, 133:403-411. 10.1053/j.gastro.2007.05.026, 17681161.
16. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Quesenberry C, Rumore GJ, Buffler PA. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007, 133:34-41. 10.1053/j.gastro.2007.04.046, 17631128.
17. Somasundar P, Riggs D, Jacksona B, Vona-Davis L, McFadden DW. Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am J Surg 2003, 186:575-578. 10.1016/j.amjsurg.2003.07.017, 14599628.
18. Beales IL, Ogunwobi OO. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol 2007, 274(1-2):60-68. 10.1016/j.mce.2007.05.017, 17618045.
19. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's oesophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006, 147:4505-4516. 10.1210/en.2006-0224, 16740977.
20. Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol 2008, 285(1-2):43-50. 10.1016/j.mce.2008.01.023, 18313838.
21. Francois F, Roper J, Goodman AJ, Pei Z, Ghumman M, Mourad M, de Perez AZ, Perez-Perez GI, Tseng CH, Blaser MJ. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut 2008, 57(1):16-24. 10.1136/gut.2007.131672, 17761783.
22. Kendall BJ, Macdonald GA, Hayward NK, Prins JB, Brown I, Walker N, Pandeya N, Green AC, Webb PM, Whiteman DC. Leptin and the risk of Barrett's oesophagus. Gut 2008, 57:448-454. 10.1136/gut.2007.131243, 18178609.
23. Wang Y, Lam KSL, Yau M, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008, 409(3):623-633. 10.1042/BJ20071492, 18177270.
24. Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 2008, 53(3):597-605. 10.1007/s10620-007-9922-1, 17763959.
25. Rubenstein JH, Dahlkemper A, Kao JY, Zhang M, Morgenstern H, McMahon L, Inadomi JM. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol 2008, 103(6):1358-1364. 10.1111/j.1572-0241.2008.01823.x, 18510610.
26. Yildirim A, Bilici M, Cayir K, Yanmaz V, Yildirim S, Tekin SB. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol 2009, 39(2):92-96. 10.1093/jjco/hyn143, 19116211.
27. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006, 94:1221-1225. 10.1038/sj.bjc.6603051, 2361397, 16570048.
28. Moons LMG, Kusters JG, Bultman E, Kuipers EJ, Van Dekken H, Tra WMW, Kleinjan A, Kwekkeboom J, van Vliet AHM, Siersema PD. Barrett's oesophagus is characterised by a predominantly humoral inflammatory response. J Pathol 2005, 207:269-276. 10.1002/path.1847, 16177953.
29. Dvorakova K, Payne C, Ramsey L. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 2004, 10:2020-2028. 10.1158/1078-0432.CCR-0437-03, 15041721.
30. Eksteen JA, Scott PA, Perry I, Jankowski JA. Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNF-alpha. Eur J Cancer Prev 2001, 10:163-166. 10.1097/00008469-200104000-00008, 11330458.
31. Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, Stuart RC, Wright N, Harrison R, Jankowski JA. Tumour necrosis factor-a in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002, 21:6071-6081. 10.1038/sj.onc.1205731, 12203119.
32. Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green A, Whiteman DC. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 2008, 17(5):1-10. 10.1158/1055-9965.EPI-07-2852, 18187387.
33. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze R, Sanchez CA, Rabinovitch PS, Reid BJ. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncology 2005, 6:945-952. 10.1016/S1470-2045(05)70431-9, 16321762.
34. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastrenterol 2003, 124:47-56.
35. Komninou D, Ayonote A, Richie JP, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood) 2003, 228(4):396-405.
36. Boyd DB. Insulin and cancer. Integr Cancer Ther 2003, 2(4):315-329. 10.1177/1534735403259152, 14713323.
37. Leitzmann MF, Koebnick C, Freedman ND, Park Y, Ballard-Barbash R, Hollenbeck A, Schatzkin A, Abnet CC. Physical activity and esophageal and gastric carcinoma in a large prospective study. Am J Prev Med 2009, 36(2):112-119. 10.1016/j.amepre.2008.09.033, 2655147, 19062237.
38. Vigen C, Bernstein L, Wu AH. Occupational physical activity and risk of adenocarcinomas of the esophagus and stomach. Int J Cancer 2006, 118(4):1004-1009. 10.1002/ijc.21419, 16152595.
39. Perusse L, Collier G, Gagnon J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Nadeau A, Zimmet PZ, Bouchard C. Acute and chronic effects of exercise on leptin levels in humans. J Appl Physiol 1997, 83(1):5-10.
40. Fatouros IG, Tournis S, Leontsini D, Jamurtas AZ, Sxina M, Thomakos P, Manousaki M, Douroudos I, Taxildaris K, Mitrakou A. Leptin and adiponectin responses in overweight inactive elderly following resistance training and detraining are intensity related. J Clin Endocrinol Metab 2005, 90(11):5970-5977. 10.1210/jc.2005-0261, 16091494.
41. Thong FSL, Hudson R, Ross R, Janssen I, Graham TE. Plasma leptin in moderately obese men: independent effects of weight loss and aerobic exercise. Am J Physiol-Endocrinol Metab 2000, 279(2):E307-E313.
42. Reseland JE, Anderssen SA, Solvoll K, Hjermann I, Urdal P, Holme I, Drevon CA. Effect of long-term changes in diet and exercise on plasma leptin concentrations. Am J Clin Nutrition 2001, 73(2):240-245.
43. Pasman WJ, Westerterp-Plantenga MS, Saris WH. The effect of exercise training on leptin levels in obese males. Am J Physiol 1998, 274(2):E280-286.
44. Ishii T, Yamakita T, Yamagami K, Yamamoto T, Miyamoto M, Koichi K, Masayuki H, Katsunobu Y, Toshihiko S, Shiro T, et al. Effect of exercise training on serum leptin levels in type 2 diabetic patients. Metabolism 2001, 50(10):1136-1140. 10.1053/meta.2001.26745, 11586483.
45. Bluher M, Bullen JW, Lee JH, Kralisch S, Fasshauer M, Kloting N, Niebauer J, Schon MR, Williams CJ, Mantzoros CS. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: Associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 2006, 91(6):2310-2316. 10.1210/jc.2005-2556, 16551730.
46. Borghouts LB, Keizer HA. Exercise and insulin sensitivity: A review. Int J Sports Med 2000, 21(1):1-12. 10.1055/s-2000-8847, 10683091.
47. Lakka TA, Lakka H-M, Rankinen T, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. Eur Heart J 2005, 26(19):2018-2025. 10.1093/eurheartj/ehi394, 15987707.
48. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol 2004, 43:1056-1061. 10.1016/j.jacc.2003.10.041, 15028366.
49. Sharma P, McQuaid K, Dent J, Fennerty B, Sampliner RE, Spechler SJ, Cameron AJ, Corley DA, Falk GW, Goldblum J, et al. A critical review of the diagnosis and management of Barrett's esophagus:The AGA Chicago Workshop. Gastrenterology 2004, 127:310-330.
50. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high grade dysplasia in Barrett's esophagus: A systematic review and meta-analysis. Am J Epidemiol 2008, 168:237-249. 10.1093/aje/kwn121, 18550563.
51. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970, 2:92-99.
52. Mathews DR, Hosker JR, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-121. 10.1007/BF00280883, 3899825.
53. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410. 10.1210/jc.85.7.2402, 10902785.
54. Cornish B. The Evaluation of multiple frequency bioelectrical impedance analysis for the assessment of body water volumes in healthy humans. Eur J Clin Nutr 1996, 50:159-164.
55. Singh S, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992, 47:1019-1024. 10.1136/thx.47.12.1019, 1021093, 1494764.
56. Fletcher G. Exercise standards for testing and training: a statement for healthcare professionals from the American heart Association. Circulation 2001, 104:1694-1740. 10.1161/hc3901.095960, 11581152.
57. Levinger I, Goodman C, Hare DL, Jerums G, Toia D, Selig S. The reliability of the 1RM strength test for untrained, middle-aged individuals. J Sci Med in Sport 2009, 12:310-316.
58. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006, 367:2086-2100. 10.1016/S0140-6736(06)68932-0, 16798392.
59. Jones R, Coyne K, Wiklund I. The Gastro-oesophageal Reflux Disease Impact Scale: a patient management tool for primary care. Aliment Pharmacol Ther 2007, 25(12):1451-1459.
60. Hallal PC, Victora CG. Reliability and validity of the International Physical Activity Questionnaire (IPAQ). Med Sci Sports Exerc 2004, (36):556. 10.1249/01.MSS.0000117161.66394.07, 15076800.
61. Booth ML. Assessment of physical activity: an international perspective. Res Q Exercise Sport 2000, 71(2):s114-120.
62. Abrahamson PE, King IB, Ulrich CM, Rudolph RE, Irwin ML, Yasui Y, Surawicz C, Lampe JW, Lampe PD, Morgan A, et al. No effect of exercise on colon mucosal prostaglandin concentrations: A 12-month randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2007, 16(11):2351-2356. 10.1158/1055-9965.EPI-07-0120, 18006923.
63. Campbell KL, McTiernan A, Li SS, Sorensen B, Yasui Y, Lampe JW, King IB, Ulrich C, Rudolph R, Irwin M, et al. Effect of a 12-month exercise intervention on the apoptotic regulating proteins Bax and Bcl-2 in colon crypts: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2007, 16(9):1767-1774. 10.1158/1055-9965.EPI-07-0291, 17855695.
64. McTiernan A, Yasui Y, Sorensen B, Irwin ML, Morgan A, Rudolph RE, Surawicz C, Lampe JW, Ayub K, Potter JD, et al. Effect of a 12-month exercise intervention on patterns of cellular proliferation in colonic crypts: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2006, 15(9):1588-1597. 10.1158/1055-9965.EPI-06-0223, 16985018.
65. McTiernan A, Tworoger S, Ulrich C, Yasui Y, Irwin M, Rajan K, Sorensen B, Rudolph R, Bowen D, Stanczyk F, et al. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res 2004, 64:2923-2928. 10.1158/0008-5472.CAN-03-3393, 15087413.
66. Monninkhof EM, Velthuis MJ, Peeters PHM, Twisk JWR, Schuit AJ. Effect of exercise on postmenopausal sex hormone levels and role of body fat: a randomized controlled trial. J Clin Oncol 2009, 27(27):4492-4499. 10.1200/JCO.2008.19.7459, 19687339.
67. McTiernan A, Tworoger S, Rajan K, Yasui Y, Sorensen B, Ulrich C, Chubak J, Stanczyk F, Bowen D, Irwin M, et al. Effect of exercise on serum androgens in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2004, 13(7):1099-1105.
68. Frank L, Sorensen B, Yasui Y, Tworoger S, Schwartz R, Ulrich C, Irwin M, Rudolph R, Rajan K, Stanczyk F, et al. Effects of exercise on metabolic risk variables in overweight postmenopausal women: a randomized clinical trial. Obes Res 2005, 13(3):615-625. 10.1038/oby.2005.66, 15833948.
69. Atkinson C, Lampe JW, Tworoger S, Ulrich C, Bowen D, Irwin M, Schwartz R, Rajan K, Yasui Y, Potter J, et al. Effects of a moderate intensity exercise intervention on estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004, 13(5):868-874.
70. McTiernan A, Sorensen B, Yasui Y, Tworoger S, Ulrich C, Irwin M, Rudolph R, Stanczyk F, Schwartz R, Potter J. No effect of exercise on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2005, 14(4):1020-1021. 10.1158/1055-9965.EPI-04-0834, 15824183.
71. Friedenreich CM, Woolcott CG, McTiernan A, Ballard-Barbash R, Brant RF, Stanczyk FZ, Terry T, Boyd NF, Yaffe MJ, Irwin ML, et al. Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol 2010, 28(9):1458-1466. 10.1200/JCO.2009.24.9557, 20159820.